Gene therapy for rare heart disease passes early safety check
NCT ID NCT07050160
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 10 people who already received LX2020 gene therapy for arrhythmogenic cardiomyopathy caused by a PKP2 gene mutation. Researchers will monitor them for years to see if the treatment remains safe and continues to help control the disease. The goal is to understand long-term effects, not to test if it works as a cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LX2020 gene therapy
What this could lead to
If successful, this could show that a single dose of gene therapy safely controls arrhythmogenic cardiomyopathy long-term, reducing the need for other treatments.
What could go wrong
This is a very small, early-stage follow-up study with only 10 participants. It is not designed to prove the therapy works, and long-term risks or loss of effect are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARRHYTHMOGENIC CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan
Ann Arbor, Michigan, 48109, United States